Cargando…

COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series

In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Zhe, Tang, Yonglan, Li, Chunhong, Sun, Chao, Zhu, Ying, Li, Zhuyi, Chang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537454/
https://www.ncbi.nlm.nih.gov/pubmed/34696220
http://dx.doi.org/10.3390/vaccines9101112
_version_ 1784588255223611392
author Ruan, Zhe
Tang, Yonglan
Li, Chunhong
Sun, Chao
Zhu, Ying
Li, Zhuyi
Chang, Ting
author_facet Ruan, Zhe
Tang, Yonglan
Li, Chunhong
Sun, Chao
Zhu, Ying
Li, Zhuyi
Chang, Ting
author_sort Ruan, Zhe
collection PubMed
description In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observation outcome is the worsening of MG symptoms within 4 weeks following COVID-19 vaccination. A total of 22 patients with MG vaccinated for COVID-19 were included. Ten (45.5%) patients had ocular MG (OMG), and 12 (55.5%) patients had generalized MG (GMG). Six (27.3%) patients were female, and the mean (SD) onset age was 45.4 (11.8) years. Nineteen (86.4%) patients were seropositive for acetylcholine receptors (AChR) antibody. Seven (31.8%) patients underwent thymectomy, and four of them confirmed thymoma pathologically. Twenty-one patients were administrated with inactivated vaccines, and the remaining one was administrated with recombinant subunit vaccine. Twenty (90.9%) patients did not present MG symptom worsening within 4 weeks of COVID-19 vaccination, and two (9.1%) patients reported slight symptom worsening but resolved quickly within a few days. Our findings suggest inactivated COVID-19 vaccines might be safe in MG patients with Myasthenia Gravis Foundation of America (MGFA) classification I to II, supporting the recommendation to promote vaccination for MG patients during the still expanding COVID-19 pandemic.
format Online
Article
Text
id pubmed-8537454
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85374542021-10-24 COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series Ruan, Zhe Tang, Yonglan Li, Chunhong Sun, Chao Zhu, Ying Li, Zhuyi Chang, Ting Vaccines (Basel) Article In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observation outcome is the worsening of MG symptoms within 4 weeks following COVID-19 vaccination. A total of 22 patients with MG vaccinated for COVID-19 were included. Ten (45.5%) patients had ocular MG (OMG), and 12 (55.5%) patients had generalized MG (GMG). Six (27.3%) patients were female, and the mean (SD) onset age was 45.4 (11.8) years. Nineteen (86.4%) patients were seropositive for acetylcholine receptors (AChR) antibody. Seven (31.8%) patients underwent thymectomy, and four of them confirmed thymoma pathologically. Twenty-one patients were administrated with inactivated vaccines, and the remaining one was administrated with recombinant subunit vaccine. Twenty (90.9%) patients did not present MG symptom worsening within 4 weeks of COVID-19 vaccination, and two (9.1%) patients reported slight symptom worsening but resolved quickly within a few days. Our findings suggest inactivated COVID-19 vaccines might be safe in MG patients with Myasthenia Gravis Foundation of America (MGFA) classification I to II, supporting the recommendation to promote vaccination for MG patients during the still expanding COVID-19 pandemic. MDPI 2021-09-29 /pmc/articles/PMC8537454/ /pubmed/34696220 http://dx.doi.org/10.3390/vaccines9101112 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ruan, Zhe
Tang, Yonglan
Li, Chunhong
Sun, Chao
Zhu, Ying
Li, Zhuyi
Chang, Ting
COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
title COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
title_full COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
title_fullStr COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
title_full_unstemmed COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
title_short COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
title_sort covid-19 vaccination in patients with myasthenia gravis: a single-center case series
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537454/
https://www.ncbi.nlm.nih.gov/pubmed/34696220
http://dx.doi.org/10.3390/vaccines9101112
work_keys_str_mv AT ruanzhe covid19vaccinationinpatientswithmyastheniagravisasinglecentercaseseries
AT tangyonglan covid19vaccinationinpatientswithmyastheniagravisasinglecentercaseseries
AT lichunhong covid19vaccinationinpatientswithmyastheniagravisasinglecentercaseseries
AT sunchao covid19vaccinationinpatientswithmyastheniagravisasinglecentercaseseries
AT zhuying covid19vaccinationinpatientswithmyastheniagravisasinglecentercaseseries
AT lizhuyi covid19vaccinationinpatientswithmyastheniagravisasinglecentercaseseries
AT changting covid19vaccinationinpatientswithmyastheniagravisasinglecentercaseseries